Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, CYTK, Eikon Therapeutics, LYEL, RLAY, and represent 90.58% of Foresite Capital Management IV's stock portfolio.
  • Added to shares of these 2 stocks: Eikon Therapeutics (+$21M), CYTK.
  • Started 1 new stock position in Eikon Therapeutics.
  • Reduced shares in these 1 stock: MAZE (-$11M).
  • Foresite Capital Management IV was a net buyer of stock by $13M.
  • Foresite Capital Management IV has $237M in assets under management (AUM), dropping by 3.21%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Foresite Capital Management IV holds 8 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 56.9 $135M 4.8M 28.25
 View chart
Cytokinetics (CYTK) 14.0 $33M +9% 503k 65.91
 View chart
Eikon Therapeutics 8.7 $21M NEW 1.9M 10.58
 View chart
Lyell Immunopharma (LYEL) 6.8 $16M 800k 20.06
 View chart
Relay Therapeutics (RLAY) 4.2 $10M 1.0M 9.95
 View chart
Xenon Pharmaceuticals (XENE) 3.9 $9.3M 160k 58.15
 View chart
Alector (ALEC) 3.5 $8.4M 3.9M 2.15
 View chart
Maze Therapeatics (MAZE) 2.0 $4.7M -69% 157k 29.85
 View chart

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings